Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly.
Here are are a few highlights from this week:
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma - The final results of the KarMMa study have been published, showing high rates of response and MRD-negativity in R/R MM patients treated with ide-cel.
- Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients - Results of the most current and comprehensive meta-analysis of CAR-T therapies in MM, with 950 patients included, demonstrated a high response rate and comparatively low rates of toxicity compared with CD19-targeted therapy.
- Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial - Adding ublituximab, an anti-CD20 mAb, to ibrutinib resulted in a statistically higher overall response rate without affecting the safety profile of ibrutinib monotherapy in patients with R/R high-risk CLL.
- CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia - In the race for universal off-the-shelf CAR-T cell treatments, new promising data come from this phase 1 study investigating CRISPR/Cas9-engineered allogeneic CD19/CD22 CAR-T cells in R/R ALL patients.
You can access our complete resource library of scientific publications here.
Last Updated on Wednesday 10 March 2021.